EXHIBIT 4.3
SECOND AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT
This Second Amended and Restated Investors' Rights Agreement (this
"Agreement") dated as of February 27, 2004 (this "Agreement") is made by and
among Momenta Pharmaceuticals, Inc., a Delaware corporation (the "Company"); the
persons and entities listed on SCHEDULE A (collectively, the "Existing
Purchasers"); the persons and entities listed on SCHEDULE B (collectively, the
"Additional Purchasers"); the persons and entities listed on SCHEDULE C
(collectively, the "Founders"); the Massachusetts Institute of Technology, a
Massachusetts corporation ("MIT") with respect to Section 2 herein; and Silicon
Valley Bank ("SVB") with respect to Section 3 and Section 5 herein. The Existing
Purchasers, the Additional Purchasers, MIT (with respect Section 2) and SVB
(with respect to Section 3 and Section 5) are sometimes referred to herein
individually as a "Purchaser" and collectively as the "Purchasers."
WHEREAS, the Company, the Existing Purchasers, the Founders, MIT (with
respect to Section 2 of the Existing Agreement (as defined herein)) and SVB
(with respect to Section 3 and Section 5 of the Existing Agreement) are parties
to an Amended and Restated Investors' Rights Agreement dated as of May 9, 2003,
as amended (the "Existing Agreement"); and
WHEREAS, the Additional Purchasers are purchasing, concurrently herewith,
certain shares of the Company's Series C Convertible Preferred Stock, $0.01 par
value per share (the "Series C Preferred Stock," together with the Company's
Series A Convertible Preferred Stock, $0.01 par value per share, the Company's
Series A Prime Convertible Preferred Stock, $0.01 par value per share, the
Company's Series A Double Prime Convertible Preferred Stock, $0.01 par value per
share (the "Series A Double Prime Preferred Stock") and the Company's Series B
Convertible Preferred Stock, $0.01 par value per share, the "Preferred Stock"),
pursuant to a Series C Convertible Preferred Stock Purchase Agreement dated as
of the date hereof; and
WHEREAS, MIT owns outstanding shares of the Company's Common Stock, $.0001
par value per share (the "Common Stock") pursuant to an Amended and Restated
Exclusive Patent License Agreement dated as of November 15, 2002 by and between
the Company and MIT (as amended, the "MIT License Agreement"); and
WHEREAS, SVB is a holder of a warrant (the "SVB Warrant") to purchase
shares of the Company's Series A Double Prime Preferred Stock; and
WHEREAS, the Company, the Purchasers, MIT (with respect to Section 2) and
SVB (with respect to Section 3 and Section 5) desire to amend and restate the
Existing Agreement to provide for certain arrangements with respect to (i) the
registration of shares of the capital stock of the Company under the Act (as
defined in Section 3 below), and (ii) certain information rights and rights of
participation; and
WHEREAS, pursuant to Section 5.5 of the Existing Agreement, such agreement
could be amended, modified, terminated or any provision therein waived upon
approval of the Company and Purchasers (as defined therein) holding at least 60%
of the shares of Preferred Stock (as defined therein) then held by all
Purchasers and any such amendment, modification, termination or waiver shall be
binding on all parties thereto (the "Requisite Approval"); and
WHEREAS, the Requisite Approval has been received by the Company, and
pursuant to Section 5.5 of the Existing Agreement, this Agreement shall be
binding upon each of the parties to the Existing Agreement.
NOW, THEREFORE, in consideration of these mutual promises and covenants set
forth herein, the parties hereto agree to the terms and conditions set forth
below:
1. COVENANTS OF THE COMPANY. The Company covenants and agrees that so long as
(i) any shares of Preferred Stock are outstanding or (ii) the Purchasers in the
aggregate hold of record beneficially not less than five percent (5%) of the
outstanding Common Stock of the Company, it will perform and observe the
following covenants and provisions:
1.1 FINANCIAL STATEMENTS. The Company will maintain books of account in
accordance with generally accepted accounting principles applied on a consistent
basis, keep full and complete financial records, and furnish the following
reports:
(a) to each Purchaser who holds at least 20,000 shares of
Preferred Stock, as soon as practicable, but in any event within one hundred
twenty (120) days after the end of the Company's 2003 fiscal year and within
ninety (90) days after the end of each fiscal year thereafter, an income
statement for such fiscal year, a balance sheet of the Company and statement of
stockholders' equity as of the end of such year, and a schedule as to the
sources and applications of funds for such year, such year-end financial reports
to be in reasonable detail, prepared in accordance with generally accepted
accounting principles ("GAAP"), and audited and certified by such independent
public accountants of nationally recognized standing selected by the Company and
approved by the Purchasers;
(b) to Purchasers who holds at least 50,000 shares of Preferred
Stock, as soon as practicable, but in any event within thirty (30) days after
the end of each month, an unaudited income statement and schedule as to the
sources and application of funds and the balance sheet as of the end of such
month; and
(c) such other financial information of the Company as the
Purchasers may reasonably request, including certificates of the principal
financial officer of the Company concerning compliance with the covenants of the
Company under this Section 1.1.
1.2 OPERATING PLAN; OTHER REPORTING. The Company will prepare and
deliver to each Purchaser on or before the first day of each fiscal year, an
annual operating plan (that will include a budget) prepared on a monthly basis
and, promptly after preparation, any revisions to such operating plan. In
addition, the Company will promptly provide to each Purchaser other customary
information and materials, including reports of adverse developments, management
letters, communications with stockholders or directors, press releases and
registration statements.
1.3 INSPECTION. The Company shall, upon reasonable prior notice to the
Company, permit authorized representatives of the Purchasers to visit and
inspect any of the properties of the Company including its books of account (and
to make copies thereof and take extracts therefrom), and to discuss the affairs,
finances and accounts of the Company with its officers,
-2-
administrative employees and independent accountants, all at the expense of the
Purchasers and at such reasonable times and as often as may be reasonably
requested.
1.4 EMPLOYEE AGREEMENTS. The Company shall require all of its employees
and consultants to enter into suitable agreements with provisions governing,
among other things, the protection of confidential information, assignment of
intellectual property, and competition with the Company.
1.5 RESERVATION OF CONVERSION STOCK. The Company will, upon any increase
in the number of shares of Common Stock issuable upon conversion of any series
of Preferred Stock, reserve additional shares of Common Stock for issuance upon
such conversion, so that the number of shares of Common Stock so reserved will
not at any time be less than the number of such shares issuable upon such
conversion.
1.6 BOARD MEETINGS. The Company agrees to hold a meeting of its Board
of Directors at least four times per year or otherwise as unanimously agreed by
the directors.
1.7 TERMINATION OF COVENANTS. The rights set forth in this Article 1
shall terminate and be of no further force or effect upon the earliest to occur
of (i) the closing of the Company's initial public offering pursuant to an
effective registration statement at a price to the public of at least $10.00 per
share (adjusted for stock splits, stock dividends and similar events) resulting
in gross proceeds to the Company of at least $15,000,000 (a "Qualified Public
Offering"), (ii) the closing of the Company's sale of all or substantially all
of its assets or the acquisition of the Company by another entity (other than an
entity that controls, or is controlled by, or is under common control with, the
Company) by means of merger, consolidation or stock purchase, and (iii) the
effective date of the later to occur of (A) the conversion of all of the Series
A Convertible Preferred Stock, (B) the conversion of all of the Series A Prime
Convertible Preferred Stock, (C) the conversion of all of the Series A Double
Prime Convertible Preferred Stock, (D) the conversion of all of the Series B
Convertible Preferred Stock and (E) the conversion of all of the Series C
Preferred Stock. Notwithstanding the foregoing, in the event that (1) the
Pricing Committee of the Company's Board of Directors approves a per share price
to the public in connection with the Company's initial public offering at less
than $10.00 per share (the "Adjusted IPO Price") (adjusted for stock splits,
stock dividends and similar events); (2) the holders of at least 66 2/3% of the
shares of Preferred Stock outstanding at that time approve the Adjusted IPO
Price; and (3) the Adjusted IPO Price is no less than $7.8463, the rights set
forth in this Article 1 shall terminate and be of no further force or effect
upon the closing of such initial public offering.
2. RIGHTS.
2.1 DEFINITIONS.
(a) "NEW SECURITIES" shall mean (i) any capital stock of the
Company whether or not currently authorized, (ii) all rights, options or
warrants to purchase capital stock, and (iii) all securities of any type
whatsoever that are, or may become, convertible into capital stock; PROVIDED,
HOWEVER, that the term "New Securities" SHALL NOT include (a) the shares of
Common Stock issuable upon the conversion of the Preferred Stock; (b) securities
issuable upon the
-3-
exercise or conversion of all rights, options or warrants to purchase capital
stock of the Company outstanding as of the date hereof; (c) issuances of shares
of Common Stock authorized by vote of the Board of Directors of the Company, or
options to purchase such shares, that are issued or granted to officers,
directors, employees or consultants of the Company; (d) securities offered to
the public pursuant to a registration statement filed with the Securities and
Exchange Commission; (e) Common Stock, Preferred Stock or other securities
issued in connection with any stock split, stock dividend, recapitalization,
reclassification or similar event by the Company; (f) securities issued to MIT
or persons designated by MIT pursuant to the MIT License Agreement; or (g)
securities issued solely in consideration for the acquisition or licensing of
technology or in connection with a corporate partnering transaction.
(b) "PURCHASER" shall include, for the purposes of this Section 2,
(i) the general partners, members, officers, or other affiliates of a Purchaser,
and (ii) MIT. The term "Purchaser" shall not include any person other than MIT
that receives Common Stock from the Company pursuant to the terms of the MIT
License Agreement unless a Purchaser subsequently transfers Common Stock to such
person. Each Purchaser may apportion its pro rata share among its general
partners, members, officers, and other affiliates in such proportions as it
deems appropriate.
2.2 PARTICIPATION RIGHT. Each Purchaser shall be entitled to a right to
purchase, on a pro rata basis (as defined in this Section 2.2), all or any part
of New Securities which the Company may, from time to time, propose to sell and
issue, subject to the terms and conditions set forth below. Such Purchaser's pro
rata share shall equal a fraction of the New Securities being issued, the
numerator of which is the number of shares of Common Stock then held by such
Purchaser plus the number of shares of Common Stock issued or issuable upon
conversion of the Preferred Stock or other securities then held by such
Purchaser, and the denominator of which is the total number of shares of Common
Stock then outstanding plus the number of shares of Common Stock issuable upon
(i) conversion of then outstanding Preferred Stock or other convertible
securities and (ii) exercise of then outstanding options, rights or warrants
(whether or not vested).
2.3 EXERCISE OF RIGHT. In the event the Company intends to issue New
Securities, it shall give each Purchaser written notice of such intention,
describing the type of New Securities to be issued, the price thereof, and the
general terms upon which the Company proposes to effect such issuance and
whether or not the failure to participate in such transaction as provided herein
would result in a Special Mandatory Conversion, as such term is defined in the
Company's certificate of incorporation (the "Sale Notice"). Each Purchaser shall
have twenty (20) calendar days from the date of any Sale Notice to agree to
purchase all or any part of its pro rata share of such New Securities and all or
any part of the pro rata share of any other Purchaser entitled to such rights
(to the extent that such other Purchaser(s) do not elect to purchase their full
pro rata share), in each case for the price and upon the general terms and
conditions specified in the Sale Notice by giving written notice to the Company
stating the quantity of New Securities to be so purchased (an "Exercise
Notice"); provided, however, that in the event that the transaction described in
a Sale Notice involves in whole or in part the payment of non-cash
consideration, or the payment of consideration over time, the Purchasers shall
have the right to elect, upon exercise of their rights set forth in this Section
2, to pay to the Company in full consideration for
-4-
the New Securities the market price of such securities which shall be the
present cash value of the consideration described in the Sale Notice as
determined by the Board of Directors of the Company in good faith. If the
Purchasers who elect to purchase their full pro rata share also elect to
purchase in the aggregate more than 100% of the New Securities, such New
Securities shall be sold to such Purchasers in accordance with their respective
pro rata share. A failure to provide the Company with written notice setting
forth the quantity of New Securities to be purchased by any Purchaser in
accordance with this Section 2 shall be deemed to be a waiver by such Purchaser
of its right to purchase any portion of its pro rata share of such New
Securities.
2.4 CLOSING. The closing of the purchase of New Securities by the
Purchasers exercising their rights hereunder ("Participating Purchasers") shall
take place at such location, date and time as the parties shall agree but not
later than forty (40) calendar days following the delivery of the Sale Notice.
At the closing, the Company shall deliver to the Participating Purchasers
certificates representing all of the New Securities to be purchased and such
other agreements executed by the Company which grant any rights or privileges to
the Participating Purchasers as are being granted to the other purchasers in
such issuance, and in any event, at the request of the Participating Purchasers,
a duly executed certificate reasonably satisfactory to the Participating
Purchasers containing a representation and warranty that, upon issuance or
transfer of such securities to the Participating Purchasers that the
Participating Purchasers will be the legal and beneficial owners of such
securities with good title thereto, free and clear of all mortgages, liens,
charges, security interests, adverse claims, pledges, encumbrances and demands
whatsoever, and that the Company has the absolute right to issue or transfer
such securities to the Participating Purchasers without the consent or approval
of any other person. At the closing, the Participating Purchasers shall deliver
to the Company (i) payment for the New Securities and (ii) such other agreements
executed by the other purchasers in such issuance which include representations
by such purchasers to the Company or restrict such purchasers' rights with
respect to the New Securities, and in any event, at the request of the Company,
a duly executed certificate reasonably satisfactory to the Company containing
such representations and warranties of the Participating Purchasers with respect
to federal and state securities laws. The certificates representing the equity
securities may contain a legend stating that they are issued subject to the
registration requirements of the Securities Act of 1933, as amended, and
applicable state securities laws.
2.5 FAILURE TO EXERCISE RIGHT. In the event the Purchasers fail to
exercise the foregoing participation right with respect to any New Securities
within the periods specified by Sections 2.3 above, the Company may within one
hundred and twenty (120) calendar days after the delivery of the Sale Notice
sell any or all of such New Securities not agreed to be purchased by the
Purchasers, at a price and upon general terms no more favorable to the
purchasers thereof than specified in the Sale Notice. In the event the Company
has not sold such New Securities within such 120-day period, the Company shall
not thereafter issue or sell any New Securities without first offering such New
Securities to the Purchasers in the manner provided in Section 2.3.
2.6 TERMINATION OF RIGHTS. The rights set forth in this Article 2 shall
terminate and be on no further force or effect upon the closing of a Qualified
Public Offering.
3. REGISTRATION RIGHTS. The Company covenants and agrees as follows:
-5-
3.1 DEFINITIONS. As used in this Section 3, the following terms shall
have the following meanings:
(a) "ACT" means the Securities Act of 1933, as amended.
(b) "FORM S-1" means such form under the Act as in effect on the
date hereof, or any registration form under the Act subsequently adopted by the
SEC which permits the registration of securities under the Act for which no
other form is authorized or prescribed.
(c) "FORM S-3" means such form under the Act as in effect on the
date hereof or any registration form under the Act subsequently adopted by the
SEC which permits inclusion or incorporation of substantial information by
reference to other documents filed by the Company with the SEC.
(d) "PREFERRED HOLDER" means (i) a Purchaser and any persons or
entities to whom the rights granted under this Section 3 are transferred by the
Purchaser and (ii) their successors or assigns as permitted under Section 4
below.
(e) "HOLDERS" means (i) a Preferred Holder and (ii) ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇., ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇ ▇. ▇▇▇▇▇ and
their Permitted Transferees.
(f) "PERMITTED TRANSFEREE" means, with respect to ▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇., ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇ ▇. ▇▇▇▇▇ (i)
such Holder's spouse, parents and the linear descendants of such Holder's
parents (collectively, "family members") to whom Registrable Securities are
transferred; and (ii) any trust to which Registrable Securities are transferred
(A) in respect of which such Holder serves as trustee, provided that the trust
instrument governing such trust shall provide that such Founder, as trustee,
shall retain sole and exclusive control over the voting and disposition of such
Registrable Securities until the termination of this Agreement or (B) for the
benefit solely of such Holder's family members; provided, that no person or
entity shall be a Permitted Transferee unless such transferee delivers a written
notice to the Company at the time of such transfer stating the name and address
of the transferee and identifying the Registrable Securities with respect to
which such rights are being assigned.
(g) "1934 ACT" shall mean the Securities Exchange Act of 1934, as
amended.
(h) The terms "REGISTER," "REGISTERED," and "REGISTRATION" refer
to a registration effected by preparing and filing a registration statement or
similar document in compliance with the Act, and the declaration or ordering of
effectiveness of such registration statement or document.
(i) "REGISTRABLE SECURITIES" means (i) the Common Stock held by
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇., ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇ ▇. ▇▇▇▇▇
and their Permitted Transferees, (ii) the Common Stock issuable or issued upon
conversion of the Preferred Stock or upon the conversion of the shares of Series
A Double Prime Preferred Stock issuable upon exercise of the SVB Warrant, and
(iii) any Common Stock of the Company issued as (or issuable upon the conversion
or exercise of any warrant, right, or other security which is
-6-
issued as) a dividend or other distribution with respect to, or in exchange for
or in replacement of, the shares referenced in (i) and (ii) above, excluding in
all cases, however, any Registrable Securities sold by a person in a transaction
in which the rights under this Section 3 are not properly assigned.
(j) "OUTSTANDING REGISTRABLE SECURITIES" shall mean the number of
shares of Common Stock outstanding that are, and the number of shares of Common
Stock issuable pursuant to then exercisable or convertible securities which are,
Registrable Securities.
(k) "SEC" shall mean the Securities and Exchange Commission.
3.2 DEMAND REGISTRATION.
(a) If the Company shall receive at any time after the earlier of
(1) May 9, 2006, and (2) six months after the Company's initial public offering,
a written notice from the Preferred Holders constituting the holder(s) of at
least fifty percent (50%) of the Outstanding Registrable Securities then held by
Preferred Holders requesting that the Company effect a registration statement
under the Act with respect to all or a part of the Registrable Securities held
by such Preferred Holder or Preferred Holders, then the Company shall:
(i) within ten (10) days of the receipt thereof, give
written notice of such request to all Preferred Holders; and
(ii) effect as soon as practicable, and in any event within
ninety (90) days of the receipt of such request, the registration under the Act
of all Registrable Securities which the Preferred Holders request to be
registered (by notice to the Company within thirty (30) days of the mailing of
the notice sent by the Company in accordance with Section 3.2(a)(i)), subject to
the limitations of Subsection 3.2(b).
(b) If the Preferred Holders initiating the registration request
hereunder ("Initiating Holders") intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the
Company as a part of their request made pursuant to subsection 3.2(a) and the
Company shall include such information in the written notice referred to in
subsection 3.2(a). The underwriter will be selected by the Company and shall be
reasonably acceptable to a majority in interest of the Initiating Holders. In
such event, the right of any Preferred Holder to include Registrable Securities
in such registration shall be conditioned upon such Preferred Holder's
participation in such underwriting and the inclusion of such Preferred Holder's
Registrable Securities in the underwriting (unless otherwise mutually agreed by
a majority in interest of the Initiating Holders and such Preferred Holder) to
the extent provided herein. All Preferred Holders proposing to distribute their
securities through such underwriting shall (together with the Company as
provided in subsection 3.5(e)) enter into an underwriting agreement in customary
form with the underwriter or underwriters selected for such underwriting.
Notwithstanding any other provision of this Section 3.2, if the underwriter
advises the Company in writing that marketing factors require a limitation of
the number of shares to be underwritten, then the Company shall so advise all
Preferred Holders of Registrable Securities which would otherwise be
underwritten pursuant hereto, and the number of shares of Registrable Securities
that may be included in the underwriting shall be allocated among all
-7-
Preferred Holders thereof, including the Initiating Holders, in proportion (as
nearly as practicable) to the amount of Registrable Securities of the Company
owned by each Preferred Holder; provided, however, that the number of shares of
Registrable Securities to be included in such underwriting shall not be reduced
unless all other securities are first entirely excluded from the underwriting.
(c) Notwithstanding the foregoing, if the Company shall furnish to
Preferred Holders requesting registration pursuant to this Section 3.2 a
certificate signed by the President of the Company stating that in the good
faith judgment of the Board of Directors of the Company it would be seriously
detrimental to the Company and its stockholders for a registration statement to
be filed and it is therefore essential to defer the filing of such registration
statement, then the Company shall have the right to defer taking action with
respect to such filing for a period of not more than one hundred twenty (120)
days after receipt of the request of the Initiating Holders. This deferral right
may not be exercised by the Company more than once in any 12-month period.
(d) In addition, the Company shall not be obligated to effect, or
to take any action to effect, any registration pursuant to this Section 3.2
after the Company has effected two (2) registrations on Form S-1 pursuant to
this Section 3.2 and such registration statements have been declared or ordered
effective and the sales of Registrable Securities under such registration
statements have closed.
(e) No incidental right under this Section 3.2 shall be construed
to limit any registration required under Section 3.3 or Section 3.4 herein.
3.3 "PIGGY-BACK" REGISTRATION.
(a) If (but without any obligation to do so) the Company proposes
to register (including for this purpose a registration effected by the Company
for stockholders other than the Preferred Holders) any of its stock or other
securities under the Act in connection with the public offering of such
securities solely for cash, other than (i) a registration relating solely to the
sale of securities to participants in a stock plan, (ii) a registration on any
form which does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the
Registrable Securities, (iii) a registration on Form S-4 (or any successor form)
relating solely to a transaction pursuant to the SEC's Rule 145, or (iv) a
registration relating to the initial public offering of the Company's Common
Stock (so long as such registration does not include any shares of Common Stock
registered on account of any person other than the Company), the Company shall,
at such time, promptly give each Holder written notice of such registration.
Upon the written request of each Holder given within twenty (20) days after the
mailing of such notice by the Company in accordance with Section 5.4, the
Company shall, subject to the provisions of subsection 3.3(b), cause to be
registered under the Act all of the Registrable Securities that each such Holder
has requested to be registered.
(b) In connection with any offering involving an underwriting of
shares of the Company's capital stock, the Company shall not be required under
this Section 3.3 to include any of the Holders' securities in such underwriting
unless such Holders accept the terms of the underwriting as agreed upon between
the Company and the underwriters selected by it (or by
-8-
other persons entitled to select the underwriters), and then only in such
quantity as the underwriters determine in their sole discretion will not
jeopardize the success of the offering by the Company. If the total amount of
securities, including Registrable Securities, requested by stockholders to be
included in such offering exceeds the amount of securities to be sold (other
than by the Company) that the underwriters determine in their sole discretion is
compatible with the success of the offering, then the Company shall be required
to include in the offering only that number of such securities, including
Registrable Securities, which the underwriters determine in their sole
discretion will not jeopardize the success of the offering; provided, however,
there shall first be excluded from such registration statement all shares of
Common Stock sought to be included therein by (i) any director, consultant,
officer, or employee of the Company or any subsidiary of the Company other than
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇., ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇ ▇. ▇▇▇▇▇,
(ii) stockholders exercising any contractual or incidental registration rights
subordinate and junior to the rights of the Preferred Holders of Registrable
Securities, and (iii) stockholders who do not have contractual registration
rights. If after such shares are excluded, the underwriters shall determine in
their sole discretion that the number of securities which remain to be included
in the offering exceeds the amount of securities to be sold that the
underwriters determine is compatible with the success of the offering, then the
Registrable Securities to be included, if any, shall be apportioned pro rata
among the Holders providing notice of their desire to participate in the
offering according to the total amount of securities entitled to be included
therein owned by each selling Holder or in such other proportions as shall
mutually be agreed to by such Holders. For purposes of the preceding sentence
concerning apportionment, for any selling Holder which is a partnership, limited
liability company or corporation, the partners, members, retired members,
retired partners, and stockholders of such Holder, or the estates and family
members of any such partners, members, retired members and retired partners and
any trusts for the benefit of any of the foregoing persons shall be deemed to be
a single "selling Holder," and any pro rata reduction with respect to such
"selling Holder" shall be based upon the aggregate amount of shares carrying
registration rights owned by all entities and individuals included in such
"selling Holder," as defined in this sentence.
(c) No incidental right under this Section 3.3 shall be construed
to limit any registration required under Section 3.2 or Section 3.4 herein.
3.4 FORM S-3 REGISTRATION. In case the Company shall receive from any
Preferred Holder or Preferred Holders constituting the holder(s) of at least
twenty five percent (25%) of the Outstanding Registrable Securities then held by
Preferred Holders a written request or requests that the Company effect a
registration on Form S-3 and any related qualification or compliance with
respect to all or a part of the Registrable Securities owned by such Preferred
Holder or Preferred Holders, the Company agrees:
(a) to promptly give written notice of the proposed registration,
and any related qualification or compliance, to all other Holders; and
(b) as soon as practicable after receiving such a request, to
effect such registration and all such qualifications and compliances as may be
so requested and as would permit or facilitate the sale and distribution of all
or such portion of such Preferred Holder's or Preferred Holders' Registrable
Securities as are specified in such request, together with all or
-9-
such portion of the Registrable Securities of any other Holder or Holders
joining in such request as are specified in a written request given within
fifteen (15) days after receipt of such written notice from the Company;
provided, however, that the Company shall not be obligated to effect any such
registration, qualification, or compliance pursuant to this Section 3.4: (i) if
Form S-3 is not available for such offering by the Holders; (ii) if the Holders,
together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such
other securities (if any) at an aggregate price to the public of less than
$500,000; (iii) if the Company shall furnish to the Holders a certificate signed
by the President of the Company stating that in the good faith judgment of the
Board of Directors of the Company, it would be seriously detrimental to the
Company and its stockholders for such Form S-3 registration to be effected at
such time, in which event the Company shall have the right to defer the filing
of the Form S-3 registration statement for a period of not more than sixty (60)
days after receipt of the request of the Holder or Holders under this Section
3.4; provided, however, that the Company shall not utilize this right more than
once in any eighteen month period; or (iv) until the next calendar year if the
Company has effected two (2) registrations on Form S-3 (or its then equivalent)
pursuant to this Section 3.4 in a calendar year and such registrations have been
declared or ordered effective and the sales of Registrable Securities under such
registration statement have closed.
(c) Registrations effected pursuant to this Section 3.4 shall not
be counted as demands for registration or registrations effected pursuant to
Sections 3.2 or 3.3, respectively.
3.5 OBLIGATIONS OF THE COMPANY. Whenever required under this Section 3
to effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible (but subject to providing counsel to the
Holders with a reasonable opportunity to review and comment on all documents):
(a) Prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its best efforts to cause such
registration statement to become effective, and, upon the request of the Holders
of a majority of the Registrable Securities registered thereunder, keep such
registration statement effective for a period of up to one hundred twenty (120)
days or, if earlier, until the distribution contemplated in the Registration
Statement has been completed; provided, however, that (i) such 120-day period
shall be extended for a period of time equal to the period the Holder refrains
from selling any securities included in such registration at the request of an
underwriter of Common Stock (or other securities) of the Company and (ii) in the
case of any registration of Registrable Securities on Form S-3 which are
intended to be offered on a continuous or delayed basis, such 120-day period
shall be extended, if necessary, to keep the registration statement effective
until all such Registrable Securities are sold; provided, that SEC Rule 415, or
any successor rule under the Act, permits an offering on a continuous or delayed
basis; and provided further that applicable rules under the Act governing the
obligation to file a post-effective amendment permit, in lieu of filing a
post-effective amendment which (i) includes any prospectus required by Section
10(a)(3) of the Act or (ii) reflects facts or events representing a material or
fundamental change in the information set forth in the registration statement,
the incorporation by reference of information required to be included in (i) and
(ii) above to be contained in periodic reports filed pursuant to Section 13 or
15(d) of the 1934 Act in the registration statement.
-10-
(b) Prepare and file with the SEC such amendments and supplements
to such registration statement and the prospectus used in connection with such
registration statement as may be necessary to comply with the provisions of the
Act with respect to the disposition of all securities covered by such
registration statement in accordance with each Holder's intended method of
disposition.
(c) Furnish to the Holders such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the
Act, and such other documents as they may reasonably request in order to
facilitate the disposition of Registrable Securities owned by the Holders.
(d) Use its best efforts to register and qualify the securities
covered by such registration statement under such other securities or Blue Sky
laws of such jurisdictions as shall be reasonably requested by the Holders and
any managing underwriter; provided, that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or
jurisdictions, unless the Company is already subject to service in such
jurisdiction and except as may be required by the Act.
(e) In the event of any underwritten public offering, enter into
and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder
participating in such underwriting shall also enter into and perform its
obligations under such an agreement.
(f) Promptly notify each Holder of Registrable Securities covered
by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Act as a result of the happening of any event
as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then
existing.
(g) Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed.
(h) Provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such
registration.
(i) Furnish, at the request of any Holder requesting registration
of Registrable Securities pursuant to this Section 3, on the date that such
Registrable Securities are delivered to the underwriters for sale in connection
with a registration pursuant to this Section 3, if such securities are being
sold through underwriters, copies of (i) the opinion, dated as of such date, of
the counsel representing the Company for the purposes of such registration given
to the underwriters in such underwritten public offering, which opinion shall be
in such form as is reasonably satisfactory to counsel to the underwriters, and
(ii) the letter dated as of such date, from the independent certified public
accountants of the Company, to the underwriters in such
-11-
underwritten public offering, addressed to the underwriters, which letter shall
be in such form as is reasonably satisfactory to counsel to the underwriters.
3.6 FURNISH INFORMATION. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 3 with
respect to the Registrable Securities of any selling Holder that such Holder
shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be required to effect the registration of such Holder's Registrable
Securities.
3.7 EXPENSES OF DEMAND AND S-3 REGISTRATIONS. The Company shall pay all
expenses other than underwriting discounts and commissions incurred in
connection with registrations, filings, or qualifications pursuant to Sections
3.2 and 3.4, including (i) all registration, filing, and qualification fees
(including filing fees with the SEC, fees due to the National Association of
Securities Dealers and fees due for listing on any stock exchange or for
qualifying for quotation on the NASDAQ system); (ii) printers and accounting
fees; (iii) fees and disbursements of counsel for the Company; and (iv) the
reasonable fees and disbursements of one counsel for the selling Holders;
provided, however, that the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to Section 3.2 or 3.4 if
the registration request is subsequently withdrawn at the request of the holders
of a majority of the Registrable Securities then held by Preferred Holders to be
registered (in which case all Preferred Holders participating in the aborted
registration shall bear such expenses), unless the holders of a majority of the
Registrable Securities then held by Preferred Holders agree to forfeit their
rights to, as applicable, one registration under Section 3.2 (demand
registration) or one registration for that calendar year under Section 3.4 (S-3
registration); provided further, however, that if at the time of such
withdrawal, the Preferred Holders have either (i) learned of a material adverse
change in the condition, business, or prospects of the Company from that known
to the Preferred Holders at the time of their request or (ii) been informed by
the underwriters of such registration that more than 20% of the Registrable
Securities requested for registration shall not be includable therein due to
market factors, and in either such case the Preferred Holders have withdrawn the
request with reasonable promptness following such disclosure, then the Preferred
Holders shall not be required to pay such expenses and shall retain their rights
pursuant to Sections 3.2 and 3.4.
3.8 EXPENSES OF "PIGGY-BACK" REGISTRATION. The Company shall pay all
expenses incurred in connection with any registration, filing, or qualification
of Registrable Securities with respect to the registrations pursuant to Section
3.3 for each Holder, including all registration, filing, and qualification fees,
printers and accounting fees relating or apportionable thereto, and the
reasonable fees and disbursements of one counsel for the selling Holders
selected by them, but excluding underwriting discounts and commissions relating
to the Registrable Securities.
3.9 DELAY OF REGISTRATION. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 3.
3.10 INDEMNIFICATION. In the event any Registrable Securities are
included in a registration statement under this Section 3:
-12-
(a) To the extent permitted by law, the Company will indemnify and
hold harmless each Holder, any underwriter (as defined in the Act) for such
Holder, and each person (if any) who controls such Holder or underwriter within
the meaning of the Act or the 1934 Act, against any losses, claims, damages or
liabilities (joint or several) to which they may become subject under the Act,
the 1934 Act, or other federal or state law, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon any of the following statements, omissions, or violations (collectively a
"Violation"): (i) any untrue statement or alleged untrue statement of a material
fact contained in such registration statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements
therein not misleading, or (iii) any violation or alleged violation by the
Company of the Act, the 1934 Act, any state securities law, or any rule or
regulation promulgated under the Act, the 1934 Act, or any state securities law;
and the Company will pay to each such Holder, underwriter, or controlling
person, as incurred, any legal or other expenses reasonably incurred by them in
connection with investigating or defending any such loss, claim, damage,
liability, or action; provided, however, that the indemnity agreement contained
in this subsection 3.10(a) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability, or action if such settlement is effected
without the consent of the Company (which consent shall not be unreasonably
withheld), nor shall the Company be liable in any such case for any such loss,
claim, damage, liability, or action to the extent that it arises out of or is
based upon a Violation which occurs in reliance upon and in conformity with
written information furnished expressly for use in connection with such
registration by any such Holder, underwriter or controlling person.
(b) To the extent permitted by law, each selling Holder severally
and not jointly will indemnify and hold harmless the Company, each of its
directors, each of its officers who has signed the registration statement, each
person (if any) who controls the Company within the meaning of the Act, any
underwriter, any other Holder selling securities in such registration statement,
and any controlling person of any such underwriter or other Holder, against any
losses, claims, damages or liabilities (joint or several) to which any of the
foregoing persons may become subject, under the Act, the 1934 Act, or other
federal or state law, insofar as such losses, claims, damages or liabilities (or
actions in respect thereto) arise out of or are based upon any Violation, in
each case to the extent (and only to the extent) that such Violation occurs in
reliance upon and in conformity with written information furnished by such
Holder expressly for use in connection with such registration; and each such
Holder will pay, as incurred, any legal or other expenses reasonably incurred by
any person intended to be indemnified pursuant to this subsection 3.10(b), in
connection with investigating or defending any such loss, claim, damage,
liability, or action; provided, however, that the indemnity agreement contained
in this subsection 3.10(b) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability, or action if such settlement is effected
without the consent of the Holder, which consent shall not be unreasonably
withheld; and further provided that in no event shall any indemnity under this
subsection 3.10(b) exceed the net proceeds from the offering received by such
Holder.
(c) Promptly after receipt by an indemnified party under this
Section 3.10 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party
-13-
under this Section 3.10, deliver to the indemnifying party a written notice of
the commencement thereof and the indemnifying party shall have the right to
participate in, and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume the defense
thereof with counsel mutually satisfactory to the parties; provided, however,
that an indemnified party (together with all other indemnified parties which may
be represented without conflict by one counsel) shall have the right to retain
one separate counsel and participate in the defense, with the fees and expenses
to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate
due to actual or potential differing interests between such indemnified party
and any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time of
the commencement of any such action, if prejudicial to its ability to defend
such action, shall relieve such indemnifying party of any liability to the
indemnified party under this Section 3.10, but the omission so to deliver
written notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Section
3.10.
(d) If the indemnification provided for in this Section 3.10 is
held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage, or expense referred to
herein, then the indemnifying party, in lieu of indemnifying such indemnified
party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, liability, claim, damage, or expense
in such proportion as is appropriate to reflect the relative fault of the
indemnifying party, on the one hand, and of the indemnified party, on the other,
in connection with the statements or omissions that resulted in such loss,
liability, claim, damage, or expense as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.
(e) Notwithstanding the foregoing, to the extent that the
provisions relating to indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public
offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control.
(f) The obligations of the Company and Holders under this Section
3.10 shall survive the completion of any offering of Registrable Securities in a
registration statement under this Section 3, and otherwise.
3.11 REPORTS UNDER SECURITIES EXCHANGE ACT OF 1934. With a view to making
available to the Holders the benefits of SEC Rule 144 and any other rule or
regulation of the SEC that may at any time permit a Holder to sell securities of
the Company to the public without registration or pursuant to a registration on
Form S-3, the Company agrees to use its best efforts:
(a) to make and keep public information available, as those terms
are understood and defined in SEC Rule 144, at all times after ninety (90) days
after the effective
-14-
date of the first registration statement filed by the Company for the offering
of its securities to the general public;
(b) to take such action, including the voluntary registration of
its Common Stock under Section 12 of the 1934 Act, as is necessary to enable the
Holders to utilize Form S-3 for the sale of their Registrable Securities, such
action to be taken as soon as practicable after the end of the fiscal year in
which the first registration statement filed by the Company for the offering of
its securities to the general public is declared effective;
(c) to file with the SEC in a timely manner all reports and other
documents required of the Company under the Act and the 1934 Act; and
(d) to furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144 (at
any time after ninety (90) days after the effective date of the first
registration statement filed by the Company), the Act and the 1934 Act (at any
time after it has become subject to such reporting requirements), or that it
qualifies as a registrant whose securities may be resold pursuant to Form S-3
(at any time after it so qualifies), (ii) a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by
the Company, and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC which permits the
selling of any such securities without registration or pursuant to such form.
3.12 "MARKET STAND-OFF" AGREEMENT. Each Holder hereby agrees that, during
the period of duration (not to exceed one hundred eighty (180) days) specified
by the Company and an underwriter of Common Stock or other securities of the
Company, following the effective date of a registration statement of the Company
filed under the Act with respect to the Company's initial public offering, such
Holder shall not, to the extent requested by the Company and such underwriter,
directly or indirectly sell, offer to sell, contract to sell (including any
short sale), grant any option to purchase, or otherwise transfer or dispose of
(other than to donees who agree to be similarly bound) any securities of the
Company held by it at any time during such period except Common Stock included
in such registration; provided, however, that all officers and directors of the
Company enter into similar agreements.
In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to the Registrable Securities of a
Holder (and the shares or securities of every other person subject to the
foregoing restriction) until the end of such period.
Notwithstanding the foregoing, the obligations described in this Section
3.12 shall not apply to a registration relating solely to employee benefit plans
on Form S-1 or Form S-8 or similar forms which may be promulgated in the future,
or a registration relating solely to a SEC Rule 145 transaction on Form S-4 or
similar forms which may be promulgated in the future.
3.13 TERMINATION OF REGISTRATION RIGHTS. No Holder shall be entitled to
exercise any right provided for in this Section 3 after five (5) years following
the consummation of the sale of securities pursuant to a registration statement
filed by the Company under the Act in connection with the initial firm
commitment underwritten offering of its securities to the general public.
-15-
4. TRANSFERS OF CERTAIN RIGHTS.
4.1 PERMITTED TRANSFEREES. The rights granted to the Purchasers under
Sections 1, 2 and 3 of this Agreement may be transferred or succeeded to only by
(i) any other Purchaser or any general or limited partner, member, officer, or
other affiliate of any Purchaser or (ii) any other person or entity that
acquires at least five percent (5%) of the Registrable Securities; provided,
however, that (A) the Company is given written notice by the transferee at the
time of such transfer stating the name and address of the transferee and
identifying the securities with respect to which such rights are being assigned,
(B) the transferee is not a competitor of the Company as determined in good
faith by the Board of Directors, (C) the transferee or assignee agrees in
writing to all provisions contained in this Agreement and (D) that such transfer
otherwise be effected in accordance with applicable securities laws.
4.2 SUBSEQUENT TRANSFERS. A transferee to whom rights are transferred
pursuant to this Section 4 may not again transfer such rights to any other
person or entity, other than as provided in Section 4.1 above.
4.3 LEGENDS. Each certificate representing the shares of Preferred Stock
shall bear a legend indicating that any holder of the Preferred Stock shall be
subject to this Agreement.
5. MISCELLANEOUS.
5.1 SEVERABILITY. The provisions of this Agreement are severable, so
that the invalidity or unenforceability of any provision of this Agreement shall
not affect the validity or enforceability of any other term or provision of this
Agreement, which shall remain in full force and effect.
5.2 SPECIFIC PERFORMANCE. In addition to any and all other remedies that
may be available at law in the event of any breach of this Agreement, the
Purchasers shall be entitled to specific performance of the agreements and
obligations of the parties hereunder and to such other injunctive or other
equitable relief as may be granted by a court of competent jurisdiction.
5.3 GOVERNING LAW. This Agreement shall be governed by, and construed
and enforced in accordance with, the substantive laws of The Commonwealth of
Massachusetts without regard to its principles of conflicts of laws.
5.4 NOTICES. All notices, requests, consents, and other communications
under this Agreement shall be in writing and shall be deemed delivered (i) two
business days after being send by registered or certified mail, return receipt
requested, postage prepaid or (ii) one business day after being sent via a
reputable nationwide overnight courier service guaranteeing next business day
delivery, in each case to the intended recipient as set forth below:
-16-
(i) If to the Company:
Momenta Pharmaceuticals, Inc.
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: President
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
With a copy to:
▇▇▇▇ and ▇▇▇▇ LLP
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Esq.
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
(ii) If to an Existing Purchaser, at its address set forth
in SCHEDULE A hereto, or at such other address as may
have been furnished to the other parties hereto in
writing by such Existing Purchaser;
(iii) If to an Additional Purchaser, at its address set forth
in SCHEDULE B hereto, or at such other address as may
have been furnished to the other parties hereto in
writing by such Additional Purchaser; and
(iv) If to a Founder, at its address set forth in SCHEDULE C
hereto, or at such other address or addresses as may
have been furnished to the other parties hereto in
writing by such Founder.
Any party may give any notice, request, consent or other communication under
this Agreement using any other means (including, without limitation, personal
delivery, messenger service, telecopy, first class mail or electronic mail), but
no such notice, request, consent or other communication shall be deemed to have
been duly given unless and until it is actually received by the party for whom
it is intended. Any party may change the address to which notices, requests,
consents or other communications hereunder are to be delivered by giving the
other parties notice in the manner set forth in this Section.
5.5 COMPLETE AGREEMENT; AMENDMENTS. This Agreement constitutes the full
and complete agreement of the parties hereto with respect to the subject matter
hereof, and supersedes all prior agreements and understandings of the parties
hereto relating to such subject matter. No amendment, modification, termination
or waiver of any provision of this Agreement shall be valid unless in writing
and signed (i) by the Company and (ii) Purchasers and their permitted
transferees holding at least 60% of the shares of Common Stock issued or
issuable upon conversion of the Preferred Stock then held (or deemed held) by
all Purchasers and their permitted transferees and any such amendment,
modification, termination or waiver shall be binding on all parties hereto.
-17-
5.6 AGGREGATION. All Registrable Securities held or acquired by a
Purchaser which is a partnership or a limited liability company shall be
aggregated with Registrable Securities held or acquired by any partner or member
thereof or by any entity that controls, or is controlled by, or is under common
control with, such Purchaser for purposes of determining the availability of any
rights under this Agreement, and the exercise of any such rights may be
allocated among such affiliated entities in such manner as those affiliated
entities shall determine.
5.7 CONSTRUCTION. A reference to a Section or Schedule shall mean a
Section in or Schedule to this Agreement unless otherwise expressly stated. The
titles and headings herein are for reference purposes only and shall not in any
manner limit the construction of this Agreement which shall be considered as a
whole. The words "include," "includes" and "including" when used herein shall be
deemed in each case to be followed by the words "without limitation." Whenever
the context may require, any pronouns used herein shall include the
corresponding masculine, feminine or neuter forms, and the singular form of
names and pronouns shall include the plural and vice-versa.
5.8 COUNTERPARTS; FACSIMILE. This Agreement may be executed in any
number of counterparts, each of which shall be deemed to be an original, and all
of which together shall constitute one and the same document. This Agreement may
be executed by facsimile signatures.
5.9 STOCK SPLITS. All references to numbers of shares in this Agreement
shall be appropriately adjusted to reflect any stock dividend, split,
combination or other recapitalization of shares by the Company occurring after
the date of this Agreement.
5.10 TERMINATION OF EXISTING AGREEMENT. The Existing Agreement is
hereby terminated and of no further force or effect.
*****
-18-
IN WITNESS WHEREOF, the parties hereto have executed this Second Amended
and Restated Investors' Rights Agreement as of the date first above written.
MOMENTA PHARMACEUTICALS, INC.
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇
-------------------------------------
▇▇▇▇ ▇. ▇▇▇▇▇
President and Chief Executive Officer
[Signature Page to Second Amended and Restated Investors' Rights Agreement]
MVM INTERNATIONAL LIFE SCIENCES
FUND NO. 1 L.P.
By: MVM Limited
acting as its General Partner
By: /s/ C. P. TRINIMAN
-------------------------------------
MVM LIMITED
By: /s/ C. P. TRINIMAN
-------------------------------------
/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
----------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇
----------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇▇
/s/ C. P. TRINIMAN
----------------------------------------
▇▇▇▇ ▇▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇
----------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇▇▇
----------------------------------------
▇▇▇▇▇▇▇ ▇▇▇
/s/ ▇▇▇▇▇▇ CASDAGLI
----------------------------------------
▇▇▇▇▇▇ Casdagli
[Signature Page to Second Amended and Restated Investors' Rights Agreement]
POLARIS VENTURE PARTNERS III, L.P.
By: POLARIS VENTURE MANAGEMENT
CO. III, L.L.C., its General Partner
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
---------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Attorney-in-fact
POLARIS VENTURE PARTNERS FOUNDERS'
FUND III, L.P.
By: POLARIS VENTURE MANAGEMENT
CO. III, L.L.C., its General Partner
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
---------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Attorney-in-fact
POLARIS VENTURE PARTNERS
ENTREPRENEURS' FUND III, L.P.
By: POLARIS VENTURE MANAGEMENT
CO. III, L.L.C., its General Partner
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
---------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Attorney-in-fact
CHP II, L.P.
By: CHP II Management, LLC,
its General Partner
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇
---------------------------------
Name: ▇▇▇▇ ▇. ▇▇▇▇
Title: Managing Member
[Signature Page to Second Amended and Restated Investors' Rights Agreement]
ATLAS VENTURE FUND V, L.P.
ATLAS VENTURE PARALLEL FUND V-A, C.V.
ATLAS VENTURE PARALLEL FUND V-B, C.V.
ATLAS VENTURE ENTREPRENEURS' FUND
V, L.P.
By: Atlas Venture Associates V, L.P.
their general partner
By: Atlas Venture Associates V, Inc.
its general partner
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------------
Vice President
ATLAS VENTURE FUND VI, L.P.
ATLAS VENTURE ENTREPRENEURS' FUND
VI, L.P.
By: Atlas Venture Associates VI, L.P.
their general partner
By: Atlas Venture Associates VI, Inc.
its general partner
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------------
Vice President
ATLAS VENTURE FUND VI GMBH & CO. KG
By: Atlas Venture Associates VI, L.P.
its managing limited partner
By: Atlas Venture Associates VI, Inc.
its general partner
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------------
Vice President
[Signature Page to Second Amended and Restated Investors' Rights Agreement]
/s/ ▇▇▇▇▇▇ ▇.▇▇▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
THE ▇▇▇▇ ▇▇▇▇▇▇▇▇ PS PLAN
By:
-------------------------------------
Name:
Title:
LANSING ▇▇▇▇▇ INVESTMENTS, LLC
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
Title: President
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇ HUTT
-----------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
THE CRANE FAMILY IRREVOCABLE TRUST -
2002
By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇
-------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇, Trustee
BQ VENTURES, LLC
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Title: Managing Member
WOLF, GREENFIELD & SACKS INVESTMENT
TRUST, LLC
By:
-------------------------------------
Name:
Title:
[Signature Page to Second Amended and Restated Investors' Rights Agreement]
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇ ▇. AND ▇▇▇▇ ▇. ▇▇▇▇▇
OPERATING L.P.
By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇
-------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇
General Partner
MITHRA VENTURES, L.P.
By:MITHRA VENTURES MANAGEMENT,
LLC
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: Managing Director
With respect to Section 2 of the Agreement only:
MASSACHUSETTS INSTITUTE OF
TECHNOLOGY, INC.
By:
-------------------------------------
Name:
Title:
With respect to Sections 3 and 5 of the Agreement
only:
SILICON VALLEY BANK d/b/a SILICON
VALLEY EAST
By: /s/ R. ▇▇▇▇▇ ▇▇▇▇▇
-------------------------------------
Name: R. ▇▇▇▇▇ ▇▇▇▇▇
Title: Vice President
[Signature Page to Second Amended and Restated Investors' Rights Agreement]
FOUNDERS:
/s/ ▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
-------------------------------- -----------------------------------
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ /s/ ▇▇▇▇ ▇. ▇▇▇▇▇
-------------------------------- -----------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇. ▇▇▇▇▇
[Signature Page to Second Amended and Restated Investors' Rights Agreement]
Schedule A
NAMES AND ADDRESSES OF EXISTING PURCHASERS
Polaris Venture Partners III, L.P.
Bay Colony Corporate Center
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
Polaris Venture Partners Entrepreneurs' Fund III, L.P.
Bay Colony Corporate Center
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
Polaris Venture Partners Founders' Fund III, L.P.
Bay Colony Corporate Center
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
Massachusetts Institute of Technology
Department of Chemical Engineering
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
The ▇▇▇▇ ▇▇▇▇▇▇▇▇ PS Plan
TSRI
▇▇▇▇▇ ▇. ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇
▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇ Schimimel
Lansing ▇▇▇▇▇ Investments, LLC
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
A-1
▇▇▇▇ ▇. ▇▇▇▇▇
Momenta Pharmaceuticals, Inc.
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
The Crane Family Irrevocable Trust - 2002,
▇▇▇▇▇▇ ▇. ▇▇▇▇▇ - Trustee
▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇, #▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇ Hutt
▇▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
BQ Ventures, LLC
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Wolf, Greenfield & Sacks
Investment Trust, LLC
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇.
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
Momenta Pharmaceuticals, Inc.
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇. and ▇▇▇▇ ▇. ▇▇▇▇▇ Operating L.P.
c/o ▇▇▇▇▇ ▇. ▇▇▇▇▇ ▇▇.
▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇
▇▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇
Massachusetts Institute of Technology (with respect to Section 2 of the
Agreement only)
Treasurer's ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇ ▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
A-2
Silicon Valley Bank (with respect to Sections 3 and 5 of the Agreement only)
One Newton Executive Park, Suite 200
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
MVM International Life Sciences Fund No. 1 LP
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
MVM Limited
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ ▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Casdagli
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
CHP II, L.P.
c/o Cardinal Partners
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇ ▇. ▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
A-3
Atlas Venture Fund V, L.P.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Parallel Fund V-A, C.V.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Parallel Fund V-B, C.V.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Entrepreneurs' Fund V, L.P.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Fund VI, L.P.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Entrepreneurs' Fund VI, L.P.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Fund VI GmbH & Co. KG
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
A-4
Schedule B
NAMES AND ADDRESSES OF ADDITIONAL PURCHASERS
Polaris Venture Partners III, L.P.
Bay Colony Corporate Center
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
Polaris Venture Partners
Entrepreneurs' Fund III, L.P.
Bay Colony Corporate Center
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
Polaris Venture Partners Founders'
Fund III, L.P.
Bay Colony Corporate Center
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
MVM International Life Sciences Fund No. 1 LP
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
MVM Limited
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
B-1
▇▇▇▇▇▇ ▇▇▇▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ ▇▇▇
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
▇▇▇▇▇▇ Casdagli
▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇
CHP II, L.P.
c/o Cardinal Partners
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇ ▇▇▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
Atlas Venture Fund V, L.P.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Parallel Fund V-A, C.V.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Parallel Fund V-B, C.V.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Entrepreneurs' Fund V, L.P.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Fund VI, L.P.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Entrepreneurs' Fund VI, L.P.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Atlas Venture Fund VI GmbH & Co. KG
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
B-2
Mithra Ventures, L.P.
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
B-3
Schedule C
NAMES AND ADDRESSES OF FOUNDERS
▇▇▇▇ ▇. ▇▇▇▇▇
Momenta Pharmaceuticals, Inc.
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
Massachusetts Institute of Technology
Center for Biomedical Engineering
16-561, ▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇.
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
Massachusetts Institute of Technology
Department of Chemical Engineering
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
Momenta Pharmaceuticals, Inc.
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
C-1
AMENDMENT NO. 1 TO
SECOND AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT
THIS AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED INVESTORS' RIGHTS
AGREEMENT (this "Amendment") by and among Momenta Pharmaceuticals, Inc. a
Delaware corporation (the "Company"), and the individuals and/or entities set
forth on the signature pages hereto (the "Investors") shall be made effective as
of June 10, 2004 (the "Effective Date").
WITNESSETH:
WHEREAS, the Company, the Investors and certain other individuals and
entities are parties to that certain Second Amended and Restated Investors'
Rights Agreement dated as of February 27, 2004 (the "Investors' Rights
Agreement");
WHEREAS, pursuant to Section 5.5 of the Investors' Rights Agreement,
such agreement can be amended, modified or terminated, or any provision therein
can be waived, upon the approval of (i) the Company, and (ii) the Purchasers
holding at least sixty percent (60%) of the shares of Common Stock issued or
issuable upon conversion of the Preferred Stock then held (or deemed held) by
all Purchasers and their permitted transferees;
WHEREAS, the Investors hold the requisite amount of shares of Common
Stock issued or issuable upon conversion of the Preferred Stock currently held
by all Purchasers and their permitted transferees to amend the Investors' Rights
Agreement; and
WHEREAS, the Company and the Investors now desire to amend the
Investors' Rights Agreement to reflect mutually agreed upon revised terms in
accordance with the provisions of this Amendment.
NOW THEREFORE, in consideration of the promises and mutual covenants
contained herein, and intending to be legally bound hereby, the parties hereto
agree as follows:
1. DEFINITIONS
Capitalized terms used herein, but not otherwise defined in this
Amendment, shall have the meanings ascribed to them in the Investors' Rights
Agreement.
2. AMENDMENT
Section 3.2(d) of the Investors' Rights Agreement is hereby amended
and restated in its entirety to read as follows:
"In addition, the Company shall not be obligated to effect, or to
take any action to effect, any registration pursuant to this Section 3.2 after
the Company has effected an aggregate of two (2) registrations, whether on Form
▇-▇, ▇▇▇▇ ▇-▇ or Form S-3, if available, pursuant to this Section 3.2 and such
registration statements have been declared or ordered effective and the sales of
Registrable Securities under such registration statements have closed."
3. REFERENCE TO AND EFFECT ON THE INVESTORS' RIGHTS AGREEMENT
(a) On and after the Effective Date, each reference to "this
Agreement," "hereunder," "hereof," "herein," or words of like import shall mean
and be a reference to the Investors' Rights Agreement as amended hereby. No
reference to this Amendment need be made in any instrument or document at any
time referring to the Investors' Rights Agreement, a reference to the Investors'
Rights Agreement in any of such instrument or document to be deemed to be a
reference to the Investors' Rights Agreement as amended hereby.
(b) Except as expressly amended by this Amendment, the provisions of
the Investors' Rights Agreement shall remain in full force and effect.
4. GOVERNING LAW
This Amendment shall be governed by, and construed and enforced in
accordance with, the substantive laws of The Commonwealth of Massachusetts
without regard to its principles of conflicts of laws.
5. COUNTERPARTS
This Amendment may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute a
single instrument.
*******
IN WITNESS WHEREOF, the undersigned have caused this Amendment No. 1 to
be executed and delivered on the date first written above.
COMPANY:
MOMENTA PHARMACEUTICALS, INC.
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇
-------------------------------------------
▇▇▇▇ ▇. ▇▇▇▇▇
President and Chief Executive Officer
INVESTORS:
MVM INTERNATIONAL LIFE SCIENCES FUND NO. 1 L.P.
By: MVM Limited
acting as its General Partner
By: /s/ C.P. Triniman
------------------------------------
MVM LIMITED
By:
-------------------------------------------
-----------------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇▇
/s/ C.P. Triniman
-----------------------------------------------
▇▇▇▇ ▇▇▇▇▇▇▇▇
-----------------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO INVESTORS' RIGHTS AGREEMENT]
POLARIS VENTURE PARTNERS III, L.P.
By: POLARIS VENTURE MANAGEMENT CO. III, L.L.C.,
its General Partner
By: /s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
---------------------------------------
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Member
POLARIS VENTURE PARTNERS FOUNDERS'
FUND III, L.P.
By: POLARIS VENTURE MANAGEMENT CO. III, L.L.C.,
its General Partner
By: /s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
---------------------------------------
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Member
POLARIS VENTURE PARTNERS ENTREPRENEURS'
FUND III, L.P.
By: POLARIS VENTURE MANAGEMENT CO. III, L.L.C.,
its General Partner
By: /s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
---------------------------------------
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Member
CHP II, L.P.
By: CHP II Management, LLC,
its General Partner
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇
---------------------------------------
▇▇▇▇ ▇. ▇▇▇▇▇▇
Managing Member
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO INVESTORS' RIGHTS AGREEMENT]
ATLAS VENTURE FUND V, L.P.
ATLAS VENTURE PARALLEL FUND V-A, C.V.
ATLAS VENTURE PARALLEL FUND V-B, C.V.
ATLAS VENTURE ENTREPRENEURS' FUND V, L.P.
By: Atlas Venture Associates V, L.P.
their general partner
By: Atlas Venture Associates V, Inc.
its general partner
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
----------------------------------------
Vice President
ATLAS VENTURE FUND VI, L.P.
ATLAS VENTURE ENTREPRENEURS' FUND VI, L.P.
By: Atlas Venture Associates VI, L.P.
their general partner
By: Atlas Venture Associates VI, Inc.
its general partner
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
----------------------------------------
Vice President
ATLAS VENTURE FUND VI GMBH & CO. KG
By: Atlas Venture Associates VI, L.P.
its managing limited partner
By: Atlas Venture Associates VI, Inc.
its general partner
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
----------------------------------------
Vice President
MITHRA VENTURES, L.P.
By: MITHRA VENTURES MANAGEMENT, LLC
By: /s/ ▇▇▇▇ ▇▇▇▇
-----------------------------------
Name: ▇▇▇▇ ▇▇▇▇
Title: Managing Director
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO INVESTORS' RIGHTS AGREEMENT]
THE ▇▇▇▇ ▇▇▇▇▇▇▇▇ PS PLAN
By:
-----------------------------------
Name:
Title:
LANSING ▇▇▇▇▇ INVESTMENTS, LLC
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
-----------------------------------
Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: President
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇ Hutt
---------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
THE CRANE FAMILY IRREVOCABLE TRUST - 2002
By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇, Trustee
BQ VENTURES, LLC
By:
-----------------------------------
Name:
Title:
WOLF, GREENFIELD & SACKS INVESTMENT TRUST, LLC
By:
-----------------------------------
Name:
Title:
---------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇ ▇. and ▇▇▇▇ ▇. ▇▇▇▇▇ Operating L.P.
By:
-----------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇
General Partner
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO INVESTORS' RIGHTS AGREEMENT]